Cargando…

Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report

Background: Osimertinib is recommended either as the first-line therapy for sensitizing EGFR-mutations (FLAURA trial) or at progression to first-/second-generation EGFR inhibitors in the presence of resistance mutation T790M (AURA 3 study). It can effectively improve the prognosis of patients with N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shujun, Wang, Lili, Lou, Lei, Yang, Feng, Wang, Hefeng, Zhan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037232/ https://www.ncbi.nlm.nih.gov/pubmed/35479327 http://dx.doi.org/10.3389/fphar.2022.854277

Ejemplares similares

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
por: Hu, Yan, et al.
Publicado: (2022)

Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor–Mutated Advanced Non-Small-Cell Lung Cancer: Case Report
por: Qin, Haifeng, et al.
Publicado: (2021)

Identification of super-enhancer-driven peptidyl arginine deiminases as potential biomarkers and therapeutic targets for osimertinib-resistant non-small cell lung cancer
por: Li, Hang, et al.
Publicado: (2022)

CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients
por: Majam, Teerapat, et al.
Publicado: (2023)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
por: Shu, Yamin, et al.
Publicado: (2022)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Xianglian Pill Suppresses Inflammation and Protects Intestinal Epithelial Barrier by Promoting Autophagy in DSS Induced Ulcerative Colitis Mice
por: Wang, Bingyu, et al.
Publicado: (2021)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Feiyiliu Mixture sensitizes EGFR(Del19/T790M/C797S) mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
por: Shi, Jingjing, et al.
Publicado: (2023)

Osimertinib: Another medication related to osteonecrosis of the jaws? A case report and literature review
por: Wang, Feng, et al.
Publicado: (2022)

Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study
por: Yuan, Zheng, et al.
Publicado: (2022)

Feiyanning formula modulates the molecular mechanism of osimertinib resistance in lung cancer by regulating the Wnt/β-catenin pathway
por: Sang, Shuliu, et al.
Publicado: (2022)

Rhubarb polysaccharide and berberine co-assembled nanoparticles ameliorate ulcerative colitis by regulating the intestinal flora
por: Feng, Yifan, et al.
Publicado: (2023)

Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial
por: Yao, Jialin, et al.
Publicado: (2022)

Repairing the intestinal mucosal barrier of traditional Chinese medicine for ulcerative colitis: a review
por: Zong, Yichen, et al.
Publicado: (2023)

Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients
por: Cao, Peng, et al.
Publicado: (2022)

Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
por: Li, Xinying, et al.
Publicado: (2021)

Curcumin alleviates experimental colitis in mice by suppressing necroptosis of intestinal epithelial cells
por: Zhong, Yuting, et al.
Publicado: (2023)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
por: Zeng, Yue, et al.
Publicado: (2022)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
por: Gianni, Caterina, et al.
Publicado: (2021)

Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels
por: Li, Peiwen, et al.
Publicado: (2023)

A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy
por: Cong, Jing, et al.
Publicado: (2020)

No benefit of chemotherapy in Osimertinib-treated postoperative non-small cell lung cancer patients
por: Li, Feng, et al.
Publicado: (2021)

Corrigendum: Curcumin alleviates experimental colitis in mice by suppressing necroptosis of intestinal epithelial cells
por: Zhong, Yuting, et al.
Publicado: (2023)

Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer
por: Qin, Qiong, et al.
Publicado: (2021)

Propionate Ameliorates Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Reducing Inflammation and Oxidative Stress
por: Tong, Ling-chang, et al.
Publicado: (2016)

Mechanism of Qingchang Suppository on repairing the intestinal mucosal barrier in ulcerative colitis
por: Shan, Jingyi, et al.
Publicado: (2023)

Corrigendum: Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels
por: Li, Peiwen, et al.
Publicado: (2023)

Pathological Mechanistic Studies of Osimertinib Resistance in Non-Small-Cell Lung Cancer Cells Using an Integrative Metabolomics-Proteomics Analysis
por: Ma, Qing, et al.
Publicado: (2020)

Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma
por: Meng, Yuting, et al.
Publicado: (2021)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
por: Leonetti, Alessandro, et al.
Publicado: (2019)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis
por: Liu, Lu, et al.
Publicado: (2022)

Activating AMPK to Restore Tight Junction Assembly in Intestinal Epithelium and to Attenuate Experimental Colitis by Metformin
por: Chen, Lu, et al.
Publicado: (2018)

The mechanism of traditional medicine in alleviating ulcerative colitis: regulating intestinal barrier function
por: Xu, Qiuyun, et al.
Publicado: (2023)

The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib
por: Wang, Yun, et al.
Publicado: (2023)

Ghrelin Inhibits Intestinal Epithelial Cell Apoptosis Through the Unfolded Protein Response Pathway in Ulcerative Colitis
por: Zhang, Lin, et al.
Publicado: (2021)

MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
por: Sun, Lei, et al.
Publicado: (2021)

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
por: Fu, Kai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ooic5oddjtau9rhlquss0f6686